Signal Detection of Adverse Events Following Pneumococcal Vaccines from the Korea Adverse Event Reporting System Database, 2005–2016
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: We aimed to analyze the surveillance reports of adverse events (AEs) due to different types of pneumococcal vaccines,in addition to detecting and validating signals of pneumococcal vaccines by comparing AEs with labels. Materials and Methods: We analyzed the percentages of AEs according to vaccine type [pneumococcal polysaccharide vaccines(PPSVs) and pneumococcal conjugate vaccines (PCVs)] in children and adults using data from the Korea Adverse Event ReportingSystem (KAERS) database from 2005 to 2016. A signal was defined as an AE that met all three indices of data mining: proportionalreporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). We validated the detected signals bycalculating sensitivity, specificity, as well as positive and negative predictive values of the signals against label information. Results: Of the 39933 AE reports on vaccination, 5718 (7.0%) were related to pneumococcal vaccine. The most frequent AE aftervaccination with PPSV was fever (23.9%) in children and injection-site reaction in adults. The most frequent AE after vaccinationwith PCV in children was pharyngitis (26.2%). In total, 13 AEs met all three indices for signal detection. Among these, hypotension,apathy, sepsis, and increased serum glutamic oxaloacetic transaminase level were not listed on vaccine labels. In validation analysis,PRR and ROR performed slightly better than IC for adults who were vaccinated with PPSVs. Conclusion: Overall, 13 new signals of PPSVs, including four signals not listed on the labels, were detected. Further researchbased on additional AE reports is required to confirm the validity of these signals for children.
Abstract
Purpose: We aimed to analyze the surveillance reports of adverse events (AEs) due to different types of pneumococcal vaccines,in addition to detecting and validating signals of pneumococcal vaccines by comparing AEs with labels. Materials and Methods: We analyzed the percentages of AEs according to vaccine type [pneumococcal polysaccharide vaccines(PPSVs) and pneumococcal conjugate vaccines (PCVs)] in children and adults using data from the Korea Adverse Event ReportingSystem (KAERS) database from 2005 to 2016. A signal was defined as an AE that met all three indices of data mining: proportionalreporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). We validated the detected signals bycalculating sensitivity, specificity, as well as positive and negative predictive values of the signals against label information. Results: Of the 39933 AE reports on vaccination, 5718 (7.0%) were related to pneumococcal vaccine. The most frequent AE aftervaccination with PPSV was fever (23.9%) in children and injection-site reaction in adults. The most frequent AE after vaccinationwith PCV in children was pharyngitis (26.2%). In total, 13 AEs met all three indices for signal detection. Among these, hypotension,apathy, sepsis, and increased serum glutamic oxaloacetic transaminase level were not listed on vaccine labels. In validation analysis,PRR and ROR performed slightly better than IC for adults who were vaccinated with PPSVs. Conclusion: Overall, 13 new signals of PPSVs, including four signals not listed on the labels, were detected. Further researchbased on additional AE reports is required to confirm the validity of these signals for children.
참고문헌 (28)
- "Causes of death statistics in 2017"[URL]
- File TM Jr, "Streptococcus pneumoniae and community-acquired pneumonia : a cause for concern", Am J Med, 117(Suppl 3A), pp.39S~50S (2004)
- Schrag SJ, "Limiting the spread of resistant pneumococci : biological and epidemiologic evidence for the effectiveness of alternative interventions", Clin Microbiol Rev, 13, pp.588~601 (2000)
- Whitney CG, "Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States", N Engl J Med, 343, pp.1917~1924 (2000)
- McCormick AW, "Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States", Nat Med, 9, pp.424~430 (2003)
- Kong Y, "Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years : a randomized, double-blinded, active control, phase III trial", Hum Vaccin Immunother, 11, pp.2425~2433 (2015)
- Marra F, "Efficacy and safety of the pneumococcal conjugate-13 valent vaccine in adults", Aging Dis, 10, pp.404~418 (2019)
- Kim ES, "Elderly immunization program against invasive pneumococcal disease in Korea, 2013", Public Health Wkly Rep, 7, pp.182~186 (2014)
- "Korea National Immunization Program" (2014)[URL]
- "2017 annual report of national lot release"[URL]
- Centers for Disease Control and Prevention (CDC), "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Morb Mortal Wkly Rep, 61, pp.816~819 (2012)
- "Information sheet observed rate of vaccine reactions pneumococcal vaccine"[URL]
- Jackson LA, "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults", Vaccine, 31, pp.3577~3584 (2013)
- Jackson LA, "Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine", Vaccine, 31, pp.3585~3593 (2013)
- Guideline for adverse drug events monitoring (pharmacovigilance), "Food, Medicine and Healthcare Administration and Control Authority of Ethiopia", Food, Medicine and Healthcare Administration and Control Authority of Ethiopia, ~ (2014)
- Bate A, "A Bayesian neural network method for adverse drug reaction signal generation", Eur J Clin Pharmacol, 54, pp.315~321 (1998)
- Chan IS, "Test-based exact confidence intervals for the difference of two binomial proportions", Biometrics, 55, pp.1202~1209 (1999)
- "PNEUMOVAX®23 (pneumococcal vaccine polyvalent) package insert"[URL]
- "PRODIAX®23 (pneumococcal vaccine polyvalent) package insert"[URL]
- "Prevenar®13 (pneumococcal conjugate vaccine) package insert"[URL]
- "Synflorix® (pneumococcal conjugate vaccine)package insert"[URL]
- Miller ER, "Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System(VAERS), 1990-2013", Vaccine, 34, pp.2841~2846 (2016)
- Törling J, "Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia", Vaccine, 22, pp.96~103 (2003)
- Burwen DR, "Evaluating adverse events after vaccination in the Medicare population", Pharmacoepidemiol Drug Saf, 16, pp.753~761 (2007)
- Brivet F, "Fatal post-splenectomy pneumococcal sepsis despite pneumococcal vac-cine and penicillin prophylaxis", Lancet, 2, pp.356~357 (1984)
- Kerner A, "Association between elevated liver enzymes and C-reactive protein : possible hepatic contribution to systemic inflammation in the metabolic syndrome", Arterioscler Thromb Vasc Biol, 25, pp.193~197 (2005)
- "Newsletter of National Immunization Program 2016"[URL]
- Shimabukuro TT, "Safety monitoring in the Vaccine Adverse Event Reporting System(VAERS)", Vaccine, 33, pp.4398~4405 (2015)